Fundraising Fox
/Companies
Sign in

Solstice Oncology

Boston, US · Founded 2026 · Delaware corporation · 3 known investors

Find your way into Solstice Oncology

Sign up to see every warm intro you have to Solstice Oncology

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Solstice Oncology team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Solstice Oncology is a clinical-stage immuno-oncology company developing porustobart, a second-generation engineered CTLA-4 antibody given with anti–PD-1 therapy in the neoadjuvant (pre-surgery) setting to treat early-stage cancers. Its lead program targets microsatellite-stable stage III colon cancer, with additional early-stage solid tumor programs.

BiotechHealthtech

Founders & leadership

DFDavid Feltquate
David FeltquateChief Medical OfficerAdvisor at RA Capital
MK
Maiken Keson-BrookesChief Operating Officer & General Counsel
CL
CAROLINE LOEWNamed on SEC filing
CJ
Caroline J. LoewPresident & Chief Executive Officer

Board

ALANDREW LEVIN
ANDREW LEVINBoard directorPartner at RA Capital
JGJULIE GRANT
JULIE GRANTBoard directorGeneral Partner at Canaan Partners
EMEMILY MINKOW
EMILY MINKOWBoard directorVenture Partner at RA Capital
MH
MORGAN HALLERBoard director

Investors · 3

Forbion✓ confirmed by Solstice OncologyNaarden

How we know: the company's own site · funding news · globenewswire.com · Not right? Tell us

Canaan Partnerslisted by Canaan PartnersStamford · $500K – $20Mvia Julie Grant · board

How we know: board seat on SEC Form D · globenewswire.com · Not right? Tell us

Funding

SEC filings, press & company announcements

$121.3M disclosed across 1 of 2 rounds · 2026

▶$121.3MraisedMar 2026 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David FeltquateExecutive Officer
  • ANDREW LEVINDirector
  • JULIE GRANTDirector
  • EMILY MINKOWDirector
  • MORGAN HALLERDirector
  • Maiken Keson-BrookesExecutive Officer
  • CAROLINE LOEWExecutive Officer, Director, Promoter
Offering amount
$298.4M
Amount sold
$121.3M
First sale
Feb 2026
Incorporated
Corporation, Delaware, 2026
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

3 people who came through Solstice Oncology went on to found or lead other companies.

Julie GrantDirectorFounded Day One BiopharmaceuticalsEmily MinkowDirectorFounded Stylus MedicineAndrew LevinDirectorFounded Climb Bio

In the news

Solstice Oncology Launches with $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapyglobenewswire.com · Sep 2026

Frequently asked questions

What does Solstice Oncology do?
Solstice Oncology is a clinical-stage immuno-oncology company developing porustobart, a second-generation engineered CTLA-4 antibody given with anti–PD-1 therapy in the neoadjuvant (pre-surgery) setting to treat early-stage cancers. Its lead program targets microsatellite-stable stage III colon cancer, with additional early-stage solid tumor programs.
Who are Solstice Oncology's investors?
Solstice Oncology's investors include RA Capital, Forbion, Canaan Partners.
How much funding has Solstice Oncology raised?
Solstice Oncology has disclosed $121.3M raised across 1 of its 2 known rounds.
Where is Solstice Oncology headquartered?
Solstice Oncology is headquartered in Boston, US.